Oliver Rinner, CEO and founder of Biognosys, provides a fascinating account of the company’s unique business model and explains how its technical research into proteomics and cell expression is likely to be even more successful despite continuous technological developments.
Biognosys – a proteomics focused company – was initially founded as a spin-off of ETH Zurich, under Prof. Ruedi Aebersold’s team (one of the pioneers in the field of proteomics) nearly 10 years ago, with the claim that “the decoding of the proteome will impact the life sciences more than the genome revolution”. Why do you think so? And what potential do you foresee in this field?
"The purpose behind the creation of Biognosys was to better understand the mode of action of various drugs and biological processes by understanding the changes in the protein levels and activation."
